Introduction
Tobacco use is the leading cause of preventable deaths in the developed world, with tobacco-related deaths reaching hundreds of thousands annually. Despite this, the 1-year success rate of tobacco cessation is less than 5% (USPHS, 2008) , which means that for every 100 tobacco users who attempt to abstain, more than 95 individuals will have relapsed within a year of their quit date. A plurality of these addicts will cite weight gain as a major component in their relapse and the majority of current tobacco users will identify their fear of weight gain as the largest impediment to attempting a tobacco cessation program (Shen et al., 2014) . Even newly abstinent tobacco users who do not increase caloric intake appear to gain weight, particularly as body fat, upon tobacco cessation (Bergman et al., 2012) , and these abstinent smokers have a markedly increased risk of developing type II diabetes within the first 24 months of nicotine abstinence (Bajaj, 2012) . Equally disconcerting, however, is that prolonged nicotine use increases body fat, particularly intra-abdominal body fat (Bergman et al., 2012) , thereby increasing the waist-to-height ratio, which is the metric that most reliably predicts risk for type II diabetes, metabolic syndrome, nonalcoholic fatty liver disease, coronary artery disease, and cerebrovascular disease (Kahn et al., 2014) . As dysfunction in insulin signaling is a major cause of obesity and diabetes, it has been suggested that the insulin pathway may play a role in modulating tobacco dependence Richardson et al., 2014) . However, the genetic evidence supporting such a role for insulin signaling in nicotine dependence remains elusive.
Caenorhabditis elegans represents a powerful genetic model for studying various questions in neurobiology, including drug dependence. For example, it has been reported that C. elegans responds to nicotine in both a concentrationdependent and a time-dependent manner and shows a wide range of behavioral responses to nicotine (Feng et al., 2006; Sobkowiak et al., 2011) . C. elegans is capable of navigating up a nicotine gradient (Sellings et al., 2013) . Nicotine has also been paired with salts to probe Conditioned Stimulus -Unconditioned Stimulus (CS-US) associations in nematodes (Musselman et al., 2012) . In addition to nicotine, C. elegans has been used as a model to characterize other types of drugs of abuse, such as cocaine and ethanol (Davies et al., 2003; Davies and McIntire, 2004; Ward et al., 2009) . Interestingly, the genes mediating drug-dependent behaviors in C. elegans are found to be evolutionarily conserved. For instance, C. elegans depends on nicotinic acetylcholine receptors (nAChRs) for nicotine-induced behaviors and requires BK channels for ethanol-induced responses (Crowder, 2004; Davies and McIntire, 2004; Feng et al., 2006) .
In C. elegans, the gene daf-2 encodes an ortholog of the receptor tyrosine kinases of the insulin and insulin-like growth factor 1 (IGF-1) receptor family ( Fig. 1a ). Although only one single insulin receptor ortholog exists in C. elegans, daf-2 has splice variants for at least three distinct isoforms, each with its own putative expression pattern and specialized functions (Kwon et al., 2010; Ohno et al., 2014) . In mammals, and likely in nematodes, insulin and IGF-1 receptors are an α2/β2 heterotetramer with α-subunit ligand-binding domains and β-subunit kinase domains (Ohno et al., 2014) . The insulin and IGF signaling (IIS) pathway plays a crucial role in a host of physiological processes in C. elegans, including lifespan and aging (Kenyon, 2010) ; lipid metabolism and fat regulation (Ashrafi, 2007) ; energy homeostasis and body weight management (Daws et al., 2011) ; as well as a role in learning and memory (Labouèbe et al., 2013; Tomioka et al., 2006) . However, a role for IIS in drug-induced behaviors has not been explored in this organism. Here, we present studies that seek to investigate a genetic link between a behavioral response to nicotine and the IIS pathway.
Methods

Subjects and strains
We maintained the C. elegans strains on nematode growth medium (NGM) [50 mmol/l NaCl, 32 g/l BBL agar, 2.5 g/l peptone, 13 μmol/l cholesterol, 1 mmol/l Ca(CH 3 COO) 2 , Locomotor responses of wild-type and daf-2 worms. (a) The insulin signaling pathway in nematodes consists of the insulin and insulin-like growth factor receptor homolog, daf-2, and the kinase homologs downstream of this receptor, age-1, pdk-1, akt-1, and akt-2. The pathway culminates with daf-16, which is the only nematode FOXO transcription factor homolog in Caenorhabditis elegans. (b) Wild-type, nicotine-naive nematodes show a dose-dependent increase in their crawl speed subsequent to an acute nicotine challenge. Compared with the nicotine-free ('0 μmol/l') group, the '100 μmol/l' group crawls significantly faster, whereas the '1000 μmol/l' group crawls significantly slower, most likely because of nicotine-induced paralysis at this concentration. The '10 μmol/l' group is not significantly different from control animals (one-way ANOVA P < 0.001; post-hoc Dunnett's Multiple Comparison Test). (c) The locomotor response of nematode strains carrying alleles hypomorphic for the insulin and insulin-like growth factor signaling ortholog, DAF-2, shows a dose-dependent decrease in crawl speed in response to nicotine. As the two strains tested, daf-2(e1368) and daf-2 (e1370), were not different from one another, their data are presented here collectively. Neither the '10 μmol/l' nor the '50 μmol/l' groups were significantly different from the '0 μmol/l' group, although the '50 μmol/l' did show a trend toward significance. The '100 μmol/l' , '500 μmol/l' , and '1000 μmol/l' groups all crawled significantly slower than the nicotine-free control group when faced with an acute nicotine challenge (one-way ANOVA P < 0.001 (+/* both); post-hoc Dunnett's Multiple Comparison Test). Animals in the '1000 μmol/l' showed signs of nicotine-induced paralysis comparable with what was observed with wild-type animals, whereas the '100 μmol/l' and '500 μmol/l' worms showed normal, nonparalytic body curvature.
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1 mmol/l MgSO 4 , 25 mmol/l KH 2 PO 4 , pH 7.0] seeded with Escherichia coli (OP50) at 20°C (Avery and You, 2012) . For any strain not already in our possession, we purchased the line from the Caenorhabditis Genetics Center (University of Minnesota, Minneapolis, Minnesota, USA). For the studies presented here, we used strains carrying mutations in C. elegans insulin signaling genes. Each strain is named for the genetic mutation it carries. The following strains were used: Bristol N2 (as wild type), daf-2(e1368), daf-2(e1370), age-1 (hx546), pdk-1(sa709), akt-1(mg306), akt-2(ok393), daf-16 (mgDF46), daf-16(mu86), daf-18(e1375), and the double mutant daf-2(e1368);daf-16(mu86).
Acute nicotine-induced locomotion assay
For the acute nicotine locomotion assay, we grew C. elegans on nicotine-free NGM with a 200 μl lawn of E. coli (OP50) and picked L4 hermaphrodites onto fresh plates 16-20 h before the behavioral test depending on the genetic background. For the test, we transferred a single animal per plate containing a thinly spread lawn of 40 μl OP50 and the appropriate nicotine concentration. As described previously (Hsu et al., 2009; Liu et al., 2013) , an automated system tracked the animal as it crawled freely on the plate for 16 min. We discarded the first 11 min as the animal acclimated to the novel environment and absorbed the nicotine through the cuticle. We then calculated the average crawl speed for the last 5 min of the recording. For the wortmannin studies, the plates also contained the appropriate concentrations of the PI3K inhibitor. We excluded from analysis any animal that crawled up the side of the plate at any point. Each group included at least 20 animals.
Drugs
We used double-distilled water to dilute molecular nicotine (10, 50, 100, 500, and 1000 μmol/l) and wortmannin (10, 100, 1000 nmol/l). We applied drugs directly to the NGM and allowed them to diffuse throughout the medium for 24-48 h to ensure a uniform concentration.
Data analysis
We used one-way ANOVA with Dunnett's Multiple Comparison Test to test dose-response curves and Student's t-test for all other statistical analyses.
Results
Acute nicotine treatment stimulates locomotion in wild type but depresses it in daf-2 mutants Acute nicotine treatment induces increased locomotion in naive worms, and this increased locomotor response depends on nAChRs (Feng et al., 2006) . This increased locomotor response depends on nAChRs (Feng et al., 2006) . As reported previously, here, we also found that wild-type C. elegans increased their locomotion speed in response to an acute nicotine challenge. This acute nicotine response was dose dependent, with an optimal response to 100 μmol/l nicotine and nicotine-induced paralysis at 1000 μmol/l nicotine (Fig. 1b) .
Interestingly, we observed that, unlike wild-type animals, when exposed to nicotine, daf-2 mutants (both e1368 and e1370) showed a dose-dependent decrease in locomotor response (Fig. 1c ). As these two alleles did not differ from one another, we present them here collectively. This is not merely a defective acute nicotine response; rather, daf-2 mutants show a nicotine phenotype that appears to be a nearly complete inversion of the wild-type response.
Mutants deficient in AGE-1 show an inverted nicotine phenotype
We next tested whether other players in the IIS pathway also regulate nicotine-induced locomotor response. DAF-2 signals to the PI3K homolog, AGE-1, which catalyzes the conversion of PIP 2 into PIP 3 . We thus tested how age-1 mutants respond to nicotine challenge and found that these animals showed the same inverted nicotine phenotype as daf-2 mutants ( Fig. 2a) . We also used a pharmacological approach by testing how the PI3K inhibitor, wortmannin, affects nicotine responses. Although wild-type C. elegans exposed to nicotine and a low (10 nmol/l) dose of wortmannin responded to nicotine with an increased locomotion speed (Fig. 2b) , those animals exposed to nicotine and a moderate dose of wortmannin (100 nmol/l) recapitulated the decreased locomotor response observed from age-1 mutants (Fig. 2c ). Higher concentrations of wortmannin (1000 nmol/l), however, are toxic to C. elegans. Thus, wortmannin treatment can mimic the inverted nicotine phenotype in a dose-dependent manner. These data together show that age-1 regulates nicotine-induced behavioral responses.
C. elegans defective in genes downstream of AGE-1 show depressed nicotine phenotype
Once AGE-1 converts PIP 2 into PIP 3 , PIP 3 activates the PDK ortholog PDK-1. As such, we next focused our attention on this kinase and its downstream targets. Figure 3a shows that pdk-1 mutant animals show the same decreased locomotor response to nicotine as daf-2 and age-1 mutants. We next chose to investigate the targets of PDK, namely, AKT/PKB. The C. elegans genome encodes two AKT homologs in the IIS pathway: akt-1 and akt-2. Loss of function in either akt-1 (Fig. 3b ) or in akt-2 ( Fig. 3c ) also results in the decreased locomotor phenotype in response to an acute nicotine challenge. Therefore, mutants deficient in genes acting downstream of age-1, including pdk-1, akt-1, and akt-2, all show the same inverted behavioral phenotype as daf-2 in response to acute nicotine challenge.
DAF-16/FOXO is required for nicotine-induced locomotor responses
The FOXO family of transcription factors is the primary target of IIS. In C. elegans, daf-16 encodes the sole FOXO transcription factor. AKT-1 and AKT-2 signal to DAF-16 through phosphorylation. As daf-16 acts downstream of daf-2, mutations in daf-16 can also suppress daf-2 mutant phenotypes in dauer formation and longevity (Kenyon, Downstream kinases yield the inverted nicotine phenotype. (a) pdk-1 mutants phenocopy daf-2 mutants in response to an acute nicotine challenge. pdk-1 mutants crawl at a slower speed in response to a 100 μmol/l nicotine challenge than do pdk-1 mutants not exposed to nicotine [one-tailed t-test, P < 0.001(*)]. (b) The two Caenorhabditis elegans AKT/PKB homologs behave similarly in response to an acute 100 μmol/l nicotine challenge. akt-1 mutants decrease their crawl speed in response to a 100 μmol/l challenge compared with nicotine-naive mutants [one-tailed t-test, P < 0.001(*)].
(c) This decrease in crawl speed persists in akt-2 mutants exposed to 100 μmol/l nicotine compared with their nicotine-naive controls [one-tailed t-test, P < 0.01(*)].
2010). As the IIS pathway acts to suppress DAF-16 function, unlike other genes in the IIS pathway, daf-16 mutants usually show a phenotype distinct from those in the IIS pathway. Indeed, we found that strains carrying either of the null alleles, daf-16(mu86) or daf-16 (mgDF46), showed no notable responses to acute nicotine treatment (Fig. 4a ). As these two alleles did not differ from one another, we present them here collectively. This indicates that daf-16 is required for behavioral responses to nicotine. With the disparity in the daf-2 and daf-16 phenotypes, we next tested whether these two genes are, in fact, functioning in the same pathway to mediate an acute nicotine response. If the daf-2 and daf-16 genes act in the same pathway in this acute nicotine behavior, the daf-2;daf-16 double mutant should perform similar to the daf-16 or the daf-2 mutant alone. Indeed, daf-2;daf-16 double mutants showed the same nicotine defect as observed with the single daf-16 mutants, suggesting that these two genes, daf-2 and daf-16, are functioning in the same pathway (Fig. 4b) . Therefore, daf-16 acts downstream of the IIS pathway to modulate the acute response to nicotine challenge.
Discussion
In the current study, we present the first genetic evidence supporting a role for IIS in modulating behavioral responses to nicotine. We show that wild-type C. elegans dose dependently increases locomotor speed in response to acute nicotine treatment. Interestingly, the highest doses of nicotine elicited a paralytic effect. Such a biphasic effect of nicotine has also been observed in rodents (Jerome and Sanberg, 1987) . Rather than increasing their locomotion speed as does wild-type C. elegans, daf-2 mutants move slower when acutely challenged with nicotine. In these animals, nicotine appears to act as a depressant rather than as a stimulant.
This effect does not appear to result from a simple shift of the dose curve as no stimulatory effect of nicotine was observed at low concentrations of nicotine in daf-2 mutants. In addition, although nicotine suppresses locomotion speed in daf-2 mutants, these animals do not become paralyzed at low doses. In fact, both wild-type and daf-2 strains first show nicotine-induced paralysis at the same concentration (1000 μmol/l). Thus, the inverted nicotine phenotype observed in daf-2 mutants is not caused by a hypersensitive paralysis effect caused by nicotine.
This inverted nicotine phenotype persists throughout the kinase cascade downstream of DAF-2. C. elegans deficient in the PI3K gene, age-1, responds to nicotine with a reduced locomotor speed, and this genetic effect is recapitulated dose dependently when wild-type C. elegans experiences nicotine in the presence of the PI3K inhibitor wortmannin. As such, both genetic and pharmacologic manipulations seem to support this unique effect of an insulin signaling gene in the acute locomotor response to nicotine. Moreover, loss of function in the PDK ortholog pdk-1, or in either of the AKT genes akt-1 or akt-2, leads to a similar depressed response to nicotine. All these observations support a role for IIS genes in modulating nicotine-induced behavioral responses.
The C. elegans genome encodes a single FOXO transcription factor, DAF-16. This FOXO transcription factor is necessary for extending lifespan by decreased insulin signaling in nematodes (Kenyon, 2010) , and is crucial in a number of other phenomena that require insulin receptor activity (Kenyon, 2010; Murphy and Hu, 2013; Ohno et al., 2014) . Accordingly, we tested two separate null alleles for daf-16 in this acute nicotine paradigm. In both cases, daf-16 mutants showed no notable changes in locomotion speed in response to nicotine and could also daf-16 is necessary for a normal nicotine response. (a) As the two strains tested, daf-16(mgDF46) and daf-16(mu86), were not different from one another, their data are presented here collectively. daf-16 mutants exposed to 100 μmol/l nicotine do not crawl at a different speed than nicotine-naive daf-16/FOXO mutants (one-tailed t-test). (b) daf-2;daf-16 double mutants exposed to 100 μmol/l nicotine crawl at a speed that is not significantly different from double mutants exposed to no nicotine (one-tailed t-test). As the double mutant phenocopies the daf-16 single mutant instead of presenting a phenotype intermediate to the daf-2 and daf-16 single mutants, it is likely that these two genes are working in the same pathway in response to nicotine and daf-16 is downstream of daf-2.
suppress the inverted nicotine phenotype of daf-2 mutants, indicating that DAF-16 is required for mediating acute nicotine responses and acts downstream of IIS. IIS is known to suppress the function of DAF-16. However, daf-16 mutants do not show a phenotype opposite to that observed in daf-2 mutants, but are instead insensitive to nicotine. This is not surprising as DAF-16 is a transcription factor and regulates the expression of hundreds of genes, some of which could be required for mediating normal nicotine responses (Larsen, 2003) . Future studies are needed to identify specific DAF-16 target genes that mediate nicotine responses and explore a potential role of insulin and dopamine signaling in the rewarding or the reinforcing effects of nicotine in C. elegans.
